Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy

Marcella Reale, Romina Intorno, Raffaele Tenaglia, Claudio Feliciani, Renato C. Barbacane, Angela Santoni, Pio Conti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Bacillus Calmette-Guerin (BCG) therapy induces a local immunological response mediated by cellular immune and inflammatory reactions that enhance its anti-tumor efficacy in bladder cancer. Monocyte chemotactic protein-1 (MCP-1) and the "regulated on activation normal T expressed and secreted" chemokine (RANTES) are potent chemotactic molecules that attract monocytes and memory T cells. MCP-1 and RANTES levels in patients with superficial bladder cancer treated with intravesical instillations of BCG are significantly higher than in untreated cancer patients and controls. In the present study, the subjects were divided into three groups: (1) control subjects; (2) bladder cancer patients who did not receive BCG treatment; (3) bladder cancer patients who received intravesical administration of BCG. No differences in the basal production and expression of MCP-1 and RANTES mRNA were observed between BCG-treated and untreated patients. BCG treatment influenced the monocyte response to phytohemagglutinin (PHA) and BCG stimulation. After 24-h incubation, monocytes from BCG-treated bladder cancer patients released more MCP-1 and RANTES than those from untreated bladder cancer patients and controls. The anti-tumor effects of BCG observed in superficial bladder cancer therapy may depend on stimulation of the investigated chemokines, which attract monocytes/macrophages and memory T cells.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalCancer Immunology, Immunotherapy
Volume51
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Chemokine CCL2
Mycobacterium bovis
Chemokines
Urinary Bladder Neoplasms
Immunotherapy
Monocytes
Intravesical Administration
T-Lymphocytes
Neoplasms
Phytohemagglutinins
Therapeutics
Cellular Immunity
Macrophages
Control Groups
Messenger RNA

Keywords

  • BCG treatment
  • Bladder cancer
  • Chemokine
  • MCP-1
  • RANTES

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Reale, M., Intorno, R., Tenaglia, R., Feliciani, C., Barbacane, R. C., Santoni, A., & Conti, P. (2002). Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunology, Immunotherapy, 51(2), 91-98. https://doi.org/10.1007/s00262-001-0254-2

Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. / Reale, Marcella; Intorno, Romina; Tenaglia, Raffaele; Feliciani, Claudio; Barbacane, Renato C.; Santoni, Angela; Conti, Pio.

In: Cancer Immunology, Immunotherapy, Vol. 51, No. 2, 2002, p. 91-98.

Research output: Contribution to journalArticle

Reale, M, Intorno, R, Tenaglia, R, Feliciani, C, Barbacane, RC, Santoni, A & Conti, P 2002, 'Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy', Cancer Immunology, Immunotherapy, vol. 51, no. 2, pp. 91-98. https://doi.org/10.1007/s00262-001-0254-2
Reale, Marcella ; Intorno, Romina ; Tenaglia, Raffaele ; Feliciani, Claudio ; Barbacane, Renato C. ; Santoni, Angela ; Conti, Pio. / Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. In: Cancer Immunology, Immunotherapy. 2002 ; Vol. 51, No. 2. pp. 91-98.
@article{8f3077388f3649d9a1d37ba4f4948400,
title = "Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy",
abstract = "Bacillus Calmette-Guerin (BCG) therapy induces a local immunological response mediated by cellular immune and inflammatory reactions that enhance its anti-tumor efficacy in bladder cancer. Monocyte chemotactic protein-1 (MCP-1) and the {"}regulated on activation normal T expressed and secreted{"} chemokine (RANTES) are potent chemotactic molecules that attract monocytes and memory T cells. MCP-1 and RANTES levels in patients with superficial bladder cancer treated with intravesical instillations of BCG are significantly higher than in untreated cancer patients and controls. In the present study, the subjects were divided into three groups: (1) control subjects; (2) bladder cancer patients who did not receive BCG treatment; (3) bladder cancer patients who received intravesical administration of BCG. No differences in the basal production and expression of MCP-1 and RANTES mRNA were observed between BCG-treated and untreated patients. BCG treatment influenced the monocyte response to phytohemagglutinin (PHA) and BCG stimulation. After 24-h incubation, monocytes from BCG-treated bladder cancer patients released more MCP-1 and RANTES than those from untreated bladder cancer patients and controls. The anti-tumor effects of BCG observed in superficial bladder cancer therapy may depend on stimulation of the investigated chemokines, which attract monocytes/macrophages and memory T cells.",
keywords = "BCG treatment, Bladder cancer, Chemokine, MCP-1, RANTES",
author = "Marcella Reale and Romina Intorno and Raffaele Tenaglia and Claudio Feliciani and Barbacane, {Renato C.} and Angela Santoni and Pio Conti",
year = "2002",
doi = "10.1007/s00262-001-0254-2",
language = "English",
volume = "51",
pages = "91--98",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy

AU - Reale, Marcella

AU - Intorno, Romina

AU - Tenaglia, Raffaele

AU - Feliciani, Claudio

AU - Barbacane, Renato C.

AU - Santoni, Angela

AU - Conti, Pio

PY - 2002

Y1 - 2002

N2 - Bacillus Calmette-Guerin (BCG) therapy induces a local immunological response mediated by cellular immune and inflammatory reactions that enhance its anti-tumor efficacy in bladder cancer. Monocyte chemotactic protein-1 (MCP-1) and the "regulated on activation normal T expressed and secreted" chemokine (RANTES) are potent chemotactic molecules that attract monocytes and memory T cells. MCP-1 and RANTES levels in patients with superficial bladder cancer treated with intravesical instillations of BCG are significantly higher than in untreated cancer patients and controls. In the present study, the subjects were divided into three groups: (1) control subjects; (2) bladder cancer patients who did not receive BCG treatment; (3) bladder cancer patients who received intravesical administration of BCG. No differences in the basal production and expression of MCP-1 and RANTES mRNA were observed between BCG-treated and untreated patients. BCG treatment influenced the monocyte response to phytohemagglutinin (PHA) and BCG stimulation. After 24-h incubation, monocytes from BCG-treated bladder cancer patients released more MCP-1 and RANTES than those from untreated bladder cancer patients and controls. The anti-tumor effects of BCG observed in superficial bladder cancer therapy may depend on stimulation of the investigated chemokines, which attract monocytes/macrophages and memory T cells.

AB - Bacillus Calmette-Guerin (BCG) therapy induces a local immunological response mediated by cellular immune and inflammatory reactions that enhance its anti-tumor efficacy in bladder cancer. Monocyte chemotactic protein-1 (MCP-1) and the "regulated on activation normal T expressed and secreted" chemokine (RANTES) are potent chemotactic molecules that attract monocytes and memory T cells. MCP-1 and RANTES levels in patients with superficial bladder cancer treated with intravesical instillations of BCG are significantly higher than in untreated cancer patients and controls. In the present study, the subjects were divided into three groups: (1) control subjects; (2) bladder cancer patients who did not receive BCG treatment; (3) bladder cancer patients who received intravesical administration of BCG. No differences in the basal production and expression of MCP-1 and RANTES mRNA were observed between BCG-treated and untreated patients. BCG treatment influenced the monocyte response to phytohemagglutinin (PHA) and BCG stimulation. After 24-h incubation, monocytes from BCG-treated bladder cancer patients released more MCP-1 and RANTES than those from untreated bladder cancer patients and controls. The anti-tumor effects of BCG observed in superficial bladder cancer therapy may depend on stimulation of the investigated chemokines, which attract monocytes/macrophages and memory T cells.

KW - BCG treatment

KW - Bladder cancer

KW - Chemokine

KW - MCP-1

KW - RANTES

UR - http://www.scopus.com/inward/record.url?scp=0036118371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036118371&partnerID=8YFLogxK

U2 - 10.1007/s00262-001-0254-2

DO - 10.1007/s00262-001-0254-2

M3 - Article

VL - 51

SP - 91

EP - 98

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -